Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.95 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.95 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | CA9 | Q16790 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215341 | 0.97 | PTGS2 (1.00) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| SCHEMBL6339195 | 0.95 | PTGS2 (0.90) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| SCHEMBL6352647 | 0.89 | PTGS2 (0.80) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL212658 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| SCHEMBL6339240 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| SCHEMBL213150 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| SCHEMBL3243184 | 0.88 | PTGS2 (0.82) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL7789562 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| Sulfamide SCHEMBL7145902 | 0.87 | PTGS2 (0.81) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| SCHEMBL6352074 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| EP-1146789-B1 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2009-03-18 | — | — | EP | claimed |
| US-6492411-B1 | TREATING ARTHRITIS; REDUCED SIDE EFFECTS | G. D. SEARLE & CO. | 2002-12-10 | — | — | US | claimed |
| US-6156781-A | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G. D. SEARLE & CO. (US) | 2000-12-05 | — | — | US | claimed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | claimed |
| EP-1146789-B1 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20060167075-A1 | Modulators of FAAH | IRONWOOD PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| US-7041694-B1 | Cyclooxygenase-2 inhibition | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6486203-B1 | Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors | CORNELL RESEARCH FOUNDATION, INC. | 2002-11-26 | — | — | US | disclosed |
| US-6403630-B1 | ADMINISTERING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR ALONE OR IN COMBINATION WITH HERCEPTIN? ANTIBODY; USED TO TREAT BREAST CANCER | CORNELL RESEARCH FOUNDATION, INC. | 2002-06-11 | — | — | US | disclosed |
| US-5563165-A | PROSTAGLANDIN INHIBITOR; FDA ORANGE BOOK LISTED PATENT FOR CELEBREX | G. D. SEARL & CO. (US) | 1996-10-08 | — | — | US | disclosed |
| US-5521207-A | Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation | G.D. SEARLE & CO. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5516907-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5508426-A | ANTIARTHRITIC AGENT | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167075-A1 | Modulators of FAAH | FAAH, FAAH2, HCRTR2 | PTGS2 107/4885PTGS1 73/4885PDPK1 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.